-
Je něco špatně v tomto záznamu ?
Whole brain apparent diffusion coefficient measurements correlate with survival in glioblastoma patients
AM. Rulseh, J. Vymazal,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
Grantová podpora
NV18-04-00457
Ministerstvo Zdravotnictví Ceské Republiky
DRO (NHH, 00023884) IG174301
Ministerstvo Zdravotnictví Ceské Republiky
NLK
ProQuest Central
od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2009-07-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-01-01 do Před 1 rokem
Public Health Database (ProQuest)
od 1997-01-01 do Před 1 rokem
- MeSH
- alkylační protinádorové látky terapeutické užití MeSH
- chemoradioterapie mortalita MeSH
- difuzní magnetická rezonance metody MeSH
- glioblastom mortalita patologie terapie MeSH
- kombinovaná terapie MeSH
- lidé MeSH
- míra přežití MeSH
- nádory mozku mortalita patologie terapie MeSH
- následné studie MeSH
- počítačové zpracování obrazu metody MeSH
- prognóza MeSH
- progrese nemoci MeSH
- retrospektivní studie MeSH
- temozolomid terapeutické užití MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
INTRODUCTION: Glioblastoma (GBM) is the most common malignant primary brain tumor, and methods to improve the early detection of disease progression and evaluate treatment response are highly desirable. We therefore explored changes in whole-brain apparent diffusion coefficient (ADC) values with respect to survival (progression-free [PFS], overall [OS]) in a cohort of GBM patients followed at regular intervals until disease progression. METHODS: A total of 43 subjects met inclusion criteria and were analyzed retrospectively. Histogram data were extracted from standardized whole-brain ADC maps including skewness, kurtosis, entropy, median, mode, 15th percentile (p15) and 85th percentile (p85) values, and linear regression slopes (metrics versus time) were fitted. Regression slope directionality (positive/negative) was subjected to univariate Cox regression. The final model was determined by aLASSO on metrics above threshold. RESULTS: Skewness, kurtosis, median, p15 and p85 were all below threshold for both PFS and OS and were analyzed further. Median regression slope directionality best modeled PFS (p = 0.001; HR 3.3; 95% CI 1.6-6.7), while p85 was selected for OS (p = 0.002; HR 0.29; 95% CI 0.13-0.64). CONCLUSIONS: Our data show tantalizing potential in the use of whole-brain ADC measurements in the follow up of GBM patients, specifically serial median ADC values which correlated with PFS, and serial p85 values which correlated with OS. Whole-brain ADC measurements are fast and easy to perform, and free of ROI-placement bias.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023289
- 003
- CZ-PrNML
- 005
- 20201214125648.0
- 007
- ta
- 008
- 201125s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s11060-019-03357-y $2 doi
- 035 __
- $a (PubMed)31797235
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Rulseh, Aaron Michael $u Department of Radiology, Na Homolce Hospital, Roentgenova 2, 150 30, Prague 5, Czech Republic. aarulseh@gmail.com.
- 245 10
- $a Whole brain apparent diffusion coefficient measurements correlate with survival in glioblastoma patients / $c AM. Rulseh, J. Vymazal,
- 520 9_
- $a INTRODUCTION: Glioblastoma (GBM) is the most common malignant primary brain tumor, and methods to improve the early detection of disease progression and evaluate treatment response are highly desirable. We therefore explored changes in whole-brain apparent diffusion coefficient (ADC) values with respect to survival (progression-free [PFS], overall [OS]) in a cohort of GBM patients followed at regular intervals until disease progression. METHODS: A total of 43 subjects met inclusion criteria and were analyzed retrospectively. Histogram data were extracted from standardized whole-brain ADC maps including skewness, kurtosis, entropy, median, mode, 15th percentile (p15) and 85th percentile (p85) values, and linear regression slopes (metrics versus time) were fitted. Regression slope directionality (positive/negative) was subjected to univariate Cox regression. The final model was determined by aLASSO on metrics above threshold. RESULTS: Skewness, kurtosis, median, p15 and p85 were all below threshold for both PFS and OS and were analyzed further. Median regression slope directionality best modeled PFS (p = 0.001; HR 3.3; 95% CI 1.6-6.7), while p85 was selected for OS (p = 0.002; HR 0.29; 95% CI 0.13-0.64). CONCLUSIONS: Our data show tantalizing potential in the use of whole-brain ADC measurements in the follow up of GBM patients, specifically serial median ADC values which correlated with PFS, and serial p85 values which correlated with OS. Whole-brain ADC measurements are fast and easy to perform, and free of ROI-placement bias.
- 650 _2
- $a alkylační protinádorové látky $x terapeutické užití $7 D018906
- 650 _2
- $a nádory mozku $x mortalita $x patologie $x terapie $7 D001932
- 650 _2
- $a chemoradioterapie $x mortalita $7 D059248
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a difuzní magnetická rezonance $x metody $7 D038524
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a glioblastom $x mortalita $x patologie $x terapie $7 D005909
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a počítačové zpracování obrazu $x metody $7 D007091
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a temozolomid $x terapeutické užití $7 D000077204
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Vymazal, Josef $u Department of Radiology, Na Homolce Hospital, Roentgenova 2, 150 30, Prague 5, Czech Republic.
- 773 0_
- $w MED00002827 $t Journal of neuro-oncology $x 1573-7373 $g Roč. 146, č. 1 (2020), s. 157-162
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31797235 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214125647 $b ABA008
- 999 __
- $a ok $b bmc $g 1595608 $s 1113965
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 146 $c 1 $d 157-162 $e 20191203 $i 1573-7373 $m Journal of neuro-oncology $n J Neurooncol $x MED00002827
- GRA __
- $a NV18-04-00457 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a DRO (NHH, 00023884) IG174301 $p Ministerstvo Zdravotnictví Ceské Republiky
- LZP __
- $a Pubmed-20201125